Drugs that contain Zoledronic Acid

1. Drug name - RECLAST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates Oct, 2023

(1 year, 27 days from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates Feb, 2028

(5 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates Aug, 2028

(5 years from now)

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

2. Drug name - ZOMETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases May, 2025

(2 years from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases Nov, 2025

(3 years from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates Feb, 2028

(5 years from now)

Treatment: Multiple myeloma; bone metastases; hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE;INTRAVENOUS Discontinued
EQ 4MG BASE/5ML INJECTABLE;INTRAVENOUS Prescription
EQ 4MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.